THE NICKLES GROUP, LLC for CSL BEHRING LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 19, 2021 | $50,000 | Replaced |
| 4th Quarter - Amendment | Jan 20, 2021 | $50,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jan 20, 2021 | $50,000 | Replaced |
| 4th Quarter - Amendment | Jan 20, 2021 | $50,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues involving promoting plasma donation and convalescent plasma donation; issues involving the development hyperimmune globulin treatment; monitored issues related to H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; S. 4317, SAFE TO WORK Act; S. 4322, Safely Back to School and Back to Work Act. H.R. 133, the Consolidated Appropriations Act of 2021. Monitored S.AMDT 2562 to S. 178, Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act.
Foreign entity interest: CSL Limited, identified on Registration (LD-1), has an interest in activities of its U.S. subsidiary CSL Behring LLC on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STACEY HUGHES | — |
| EMILY PORTER | — |
| MARY BETH SAVARY TAYLOR | — |
Medicare/Medicaid MMM
Issues related to home infusion and DME self-administered therapies. Issues regarding coverage and reimbursement of biologics and plasma therapies. Monitored issues related to H.R. 2905, Medicare IVIG Access Enhancement Act. Monitored S. 2543, Prescription Drug Pricing Reduction Act of 2019. S. 3457 / H.R. 6218, Preserving Patient Access to Home Infusion Act, as it relates to access to drugs listed on the self-administered drug list. H.R. 7839, Continuing Access to In-Home IVIG Act. H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies. Issues concerning the most favored nation rule as it relates to plasma-derived products.
Foreign entity interest: CSL Limited, identified on Registration (LD-1), has an interest in activities of its U.S. subsidiary CSL Behring LLC on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STACEY HUGHES | — |
| EMILY PORTER | — |
| MARY BETH SAVARY TAYLOR | — |
Government Issues GOV
H.R. 133, the Consolidated Appropriations Act of 2021, including home infusion and DME self-administered therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREG D'ANGELO New | White House Office of Management and Budget, Associate Director of Health Programs; Senate Committee on the Budget (Sen. Gregg, Sen. Sessions, and Sen. Enzi), Professional Staff Member. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.